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This study aimed to investigate the serum levels of the cytokine TNF- and its soluble recep-
tors (sTNFR1 and sTNFR2) in patients with toxoplasmosis retinochoroidits (TR) and controls.
37 patientswith TR and 30 subjectswith positive serology for toxoplasmosis butwithout his-
tory and signs of uveitiswere included in this study. Serumconcentrations of TNF-, sTNFR1,
and sTNFR2 were determined by ELISA. Serum concentrations of TNF- and sTNFR1 were
similar in controls (mean ± SD median values; 56.57± 141.96 and 504.37± 163.87, respec-
tively) and TR patients (mean ± SD values, 121.62± 217.56 and 511.15± 189.30, respectively).
Serumconcentrations of sTNFR2werehigher in theuveitis groupwhencompared to the con-
trol group (respectively, mean ± SD values, 1734.84± 379.32 and 1442.75± 309.47; p=0.002).
There was no association between the serum levels of the molecules and the time of ﬁrst
symptoms, severity of vitreoushaze, size or localization of active lesions, levels of visual acu-ity, andpresence of vasculitis. These results suggest that TR is associatedwith changes in the
circulating levels of inﬂammatory biomarkers, but they are not correlated with local/ocular
signs.
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Toxoplasmosis is a common infection worldwide, but the dis-
ease is often asymptomatic in immunocompetent individuals.
It is oneof themost commoncausesof posterior uveitis in both
immunocompetent and immunocompromised individuals.1
∗ Corresponding author at: Laboratório de Imunofarmacologia, Departam
UFMG, Av. Antonio Carlos, 6627. – 31270-901 – Belo Horizonte, MG, Braz
E-mail address: altexr@gmail.com (A.L. Teixeira).
1413-8670 © 2012 Elsevier Editora Ltda.
http://dx.doi.org/10.1016/j.bjid.2012.07.009
Este é um artigo Open Access sob a licençaToxoplasmic retinochoroiditis (TR) is the most common iden-
tiﬁable cause of posterior uveitis in many parts of the world,
especially in Brazil.2
Few infected subjects develop ocular lesions, and it isento deBioquímica e Imunologia, Instituto deCiências Biológicas,
il.
uncertain why this happens. The intensity of the damage
to the retina and choroid depends on the virulence of the
infection and the associated inﬂammatory reaction.3,4 The
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esponse to antibiotic therapy in combination with cortico-
teroids and the clinical presentation vary signiﬁcantly, with
ome patients presenting one episode of mild inﬂammation,
nd others having multiple recurrences of severe uveitis lead-
ng to loss of sight. The immune response is likely to play a
ole in determining the evolution of disease and possibly in
he response to conventional therapy.5,6
TNF- is a cytokine secreted in response to injury or
nfection by different cell types, and it coordinates early pro-
nﬂammatory signals during innate immune response and is
esponsible for many of the associated systemic effects.7–9
NF- exerts its main effects by binding to two high-afﬁnity
ell surface receptors, TNFR1 (p55) and TNFR2 (p75).10 The
xtracellular portions of these receptors may constitute sol-
ble forms (sTNFR1 and sTNFR2) and can be measured in
he circulation.8 Since the soluble forms of TNF receptors can
ompetewith the cell-associatedTNF-receptors for TNF, itwas
uggested that they may function as inhibitors of TNF activ-
ty. Conversely, it has been shown that low concentrations
f sTNFRs stabilize the activity of TNF- by gradual cytokine
elease.11 Therefore sTNFRs may play a role as modulators of
he biological activity of TNF-. Therefore, measurement of
irculating levels of the two sTNFRs may be useful to deter-
ine the overall production of TNF-, and may be considered
ore reliable markers of inﬂammatory activity than TNF-
oncentration itself.8,12,13 Since the production of sTNFRs is
ed by TNF-, their concentrations may reﬂect TNF- activ-
ty.
Many studies have documented that TNF- is important
or controlling resistance to acute14,15 and chronic16,17 T. gondii
nfection. Experimental studies suggest that the TNF-/TNFRs
athway may be beneﬁcial for host protection against T.
ondii.18,19 Immunity to T. gondii depends on TNFR1-mediated
mmune reactions,20 and experimental studies have demon-
trated the crucial role of TNF- for controlling intracerebral
oxoplasmosis.16 In an animal model of ocular toxoplasmosis,
reatment with anti-TNF- antibodies resulted in worsening
f ocular lesions, with the development of retinal necrosis
nd marked inﬂammation of the vitreous and underlying
horoid.21
The aim of the present study was to evaluate serum lev-
ls of TNF- and sTNFRs in TR patients compared to controls.
t was also investigated whether their levels were associated
ith the clinical parameters of TR.
aterial and methods
ubjects
he study protocol adhered to the Declaration of Helsinki, and
as approved by the local institutional review board. Patients
ere informed verbally and in writing of the potential beneﬁts
nd risks of the study, and all patients signed an informed
onsent.
Adult subjects were recruited from the Uveitis Section of
he Department of Ophthalmology of the Universidade Fed-
ral de Minas Gerais - Brazil. 37 patients with acute TR were
nvited to participate in this study (16 males, 21 females,
ean age [± standard deviation, SD] 28.16± 8.83 years). No2;16(6):540–544 541
subject enrolled in this study presented autoimmune or sys-
temic infectious disease, or was under treatment for TR at
the moment of the ﬁrst evaluation. The diagnosis of TR was
based on positive serological test for T. gondii (IgG) and typi-
cal ocular lesions in the retina (i.e. gray-white focus of retinal
necrosis next to a pigmented retinal scar or in the other
eye).1,2,22
All patients underwent a detailed ocular examination,
including best-corrected visual acuity, applanation tonometry
for intraocular pressure, slit lamp examination, fundus exam-
ination with 78-D lens, and indirect ophthalmoscope. The
number and location of retinochoroidal lesions were doc-
umented for all patients by careful fundus drawings or
photographs. The intensity of the inﬂammatory process was
evaluated by the size of active retinochoroiditis lesions (graded
by optic disc diameter [DD]), the presence of retinal vasculi-
tis, and vitreous haze. Visual acuity (VA) was measured and
expressed as the logarithm of the minimum angle of resolu-
tion (logMAR).
For comparison, 30 age- (mean age 30.37± 6.46 years; p =
0.095; Mann-Whitney’s U test) and gender-matched (13 males,
17 females; p = 0.994) adult subjects with no evidence of
active ocular disease and with positive serological test (IgG
antibody) for T. gondii were recruited for the control group.
None had a history of uveitis, and each underwent a com-
plete ocular examination (identical to the uveitis group) to
rule out the presence of retinal scars suggestive of previous
TR.
Blood sampling and biochemical measurements
In all subjects, blood was collected aseptically after the ocu-
lar examination. Patientswerewith active disease andhadnot
yet received any treatment. Serum was prepared and stored at
-70 ◦C. Serum levels were tested according to the procedures
supplied by the manufacturer, using sandwich enzyme-linked
immunosorbent assays (ELISA) kits for TNF-, sTNFR1, and
sTNFR2 (DuoSet, R&D Systems – Minneapolis, Minn.,USA),
as routinely performed in this laboratory. All samples were
assayed in duplicate. The values are presented in pg/mL and
represent the mean result of the two measures. The variance
between measures was under 10%.
Statistical analysis
Statistical analysis and the graphs were performed using the
Statistical Package for Social Sciences (SPSS) for Windows
(16.0; SPSS, Inc., Chicago) and GraphPad Prism 4.00, respec-
tively. All variables were tested for normality of distribution
by means of the Kolmogorov-Smirnov test. Only the vari-
able age showednormal distribution.Non-parametric analysis
was performed using the Mann-Whitney’s U test for compar-
ison of unpaired data from two groups and the Willcoxon
test for comparison of paired data. Differences between three
groups were evaluated using the Kruskall-Wallis test. Correla-
tion analysis between age and cytokine levels was performed
using Spearman’s correlation coefﬁcient. Pearson’s test was
used for comparison of categorical data (e.g. gender). Statisti-
cal signiﬁcance was set at p<0.05.
i s . 20542 braz j infect d
Results
Thirty-seven patients and 30 healthy age- and gender-
matched controls were included in this study. There was
signiﬁcantly diminished visual acuity (VA – LogMAR) in the
TR group: means of 0.97 and 0.45, in the TR and con-
trol groups, respectively (p=0.001). The main demographic
and clinical features of patients with TR are presented in
Table 1.
There were no signiﬁcant differences in serum concentra-
tions of TNF- and sTNFR1 between TR patients and controls.
In contrast, signiﬁcantly increased levels of sTNFR2 were
found in TR patients (Table 2).
There was no correlation among TNF-, TNFR1, and TNFR2
even when controlling for TR. Correlation analyses also failed
to establish any relationship between serum levels of the
molecules and the time of ﬁrst symptoms, severity of vitre-
ous haze, size or localization of active lesions, levels of visual
acuity, and presence of vasculitis.
Table 1 – Clinical and demographic characteristics of
patients with toxoplasmic retinochoroiditis (TR) and
controls.
TR (37) Controls (30)
Male 16 13
Female 21 17
Mean age (years ± SD) 28.16 (8.83) 30.37 (6.46)
Visual acuity (LogMAR) mean (SD) 0.97 (0.86) 0.45 (0.74)
Time of ﬁrst symptoms (%)
≤ seven days 43.24 —
> seven days 56.76 —
Eye affected (%)
Right eye 54.05 (n=20) —
Left eye 45.94 (n =17) —
Both eyes 0 —
Size of lesion (%)
<1 DD 32.43 —
1- 2 DD 37.84 —
2-4 DD 27.02 —
> 4 DD 2.7 —
Vasculitis (%)*
Yes 58.33 —
No 41.66 —
Lesion location (%)
Zone 1 37.84 —
Zone 2 48.65 —
Zone 3 13.51 —
Vitreous haze
0 13.51 —
1+ 48.65 —
2+ 24.32 —
3+ 10.81 —
4+ 2.70 —
∗ One patient with 4+/4+ of vitreous haze was not considered in the
analysis.
DD, optic disc diameter.12;16(6):540–544
Discussion
There is a great controversy regarding which factors might be
responsible for the occurrence or recurrence of TR. Among
the proposed factors are the strains of parasites, hormonal
changes, and the production of some molecules that partici-
pate in the immune system, such as cytokines.1,5
A recent study suggested that the chemokine CXCL8 can
participate in the inﬂammatory process of TR and may be
a useful marker for patient follow-up.23 It has also been
suggested that polymorphisms of the genes responsible for
the production of cytokines could predispose the occurrence
and/or recurrence of TR. A study in humans found that the
genotypes related to a low production of IL-10 may be asso-
ciated with the occurrence of TR.24 Another study suggested
that genotypes related with a high production of IL-1may be
associated with TR recurrence.25
To the best of the authors’ knowledge, this is the ﬁrst study
to assess the serum levels of TNF- and sTNFRs in patients
with TR and to correlate these levels with clinical parameters.
The present results demonstrated increased levels of sTNFR2
in serum of patients with TR in comparison with controls,
but no differences in TNF- and sTNFR1 levels were found.
The meaning of this change in circulating levels of sTNFR2
in TR is uncertain. This result may represent either systemic
activation of inﬂammatory cascades or endocrine signaling at
distance.
The protective role of cytokines such as TNF- in TR has
been demonstrated in animal models.21 In humans, few stud-
ies have investigated circulating levels of TNF-, sTNFR1,
and sTNFR2 in infectious uveitis. Takase et al.26 did not ﬁnd
any signiﬁcant difference between the serum and aqueous
humor levels of TNF- in patients with anterior herpes sim-
plex uveitis, acute retinal necrosis, and Vogt-Koyanagi-Harada
uveitis. Yamamoto et al.27 analyzed blood samples of patients
with acquired ocular toxoplasmosis and congenital ocular
disease. They found higher levels of TNF- in patients with
acquired disease when compared with control subjects, but
the difference was not statistically signiﬁcant. Lahmar et al.
(2009) analyzed the levels of TNF- among other cytokines in
aqueous humor of patients with TR and another infectious
uveitis, ﬁnding similar levels of TNF- in both conditions.28
The levels of cytokines in aqueous humor did not correlate
with anydemographic or clinical variables (including degree of
uveal inﬂammation and etiology of the infection, i.e., congeni-
tal or primary acquired). Interestingly, the titers of TNF-were
signiﬁcantly higher in aqueous humor in comparison with
serum, suggesting that the cytokine is cleared more rapidly in
this compartment.28 These ﬁndings of unaltered serum lev-
els of TNF- in infectious uveitis are in agreement with the
present study. However, signiﬁcantly increased serum levels
of sTNFR2 in patients with TR were demonstrated in compar-
ison with that of controls. As previous studies have suggested
that sTNFR1 and sTNFR2 are the natural homeostatic regula-
tors of the TNF-11,29 and seem to be reliablemarkers of TNF-
activity8,12,13, the present ﬁnding of elevated sTNFR2 suggests
the involvement of TNF- in human TR.
The distinct behavior of sTNFR1 and sTNFR2 in TR is not
unique and has been reported in other infectious diseases.8,12
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Table 2 – Serum levels (pg/mL) of TNF-, sTNFR1 and sTNFR2 in toxoplasmic retinochoroidits (TR) patients and controls.
Toxoplasmic retinochoroiditis Controls p
Mean ± SD Median (interquartile range) Mean ± SD Median (interquartile range)
TNF- 121.62 ± 217.56 11.45 (0-146.33) 56.57 ± 141.96 4.71 (0-37.70) 0.258
sTNFR1 511.15 ± 189.30 452.67 (386.45-587.09) 504.37 ± 163.87 445.16 (388.15-638.01) 0.99
sTNFR2 1734.84 ± 379.32 1699.51 (1411.08-2017.30) 1442.75 ± 309.47 142.79 (115.82-162.98) 0.002
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2p-value: Mann-Whitney’s U test; SD, standard deviation; 25-75%: qua
nterestingly, a previous experimental study highlighted the
ole of TNFR1, but not TNFR2, in murine toxoplasmosis.14
ndeed TNFR1 and TNFR2 have different mechanisms of
egulation.9 Inﬂammatory stimuli such as TNF- and IL-1
ncrease the expression of TNFR2 through transcriptional acti-
ation, whereas TNFR1 is more commonly down-regulated
y these same stimuli.30,31 It is worth mentioning one study
hich undermined the role of TNFR-mediated signaling in
urine toxoplasmosis, indicating that interferon-receptor-
ediated signaling is more relevant for the activation of
erebral blood vessel endothelial cells and microglia.32
In conclusion, the present results suggest that TR is
ssociated with changes in the circulating levels of inﬂam-
atory biomarkers (sTNFR2), but they are not correlated with
ocal/ocular signs. Additional studies involving repeated mea-
urements with the same patients may elucidate a potential
ole for serum levels of sTNFRs as biomarkers of development
nd progression of TR.
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